April 15, 2014
AWHONN SmartBrief
Your bi-weekly resource for clinical news and career development
Sign up|Forward|Archive|Advertise

AWHONN SmartBrief special report:
Congenital heart defects, Part I
About 1.3 million people in the U.S. have congenital heart defects, according to the American Heart Association. The condition affects 35,000 newborns annually, or 8 out of every 1,000 births, according to the National Heart, Lung, and Blood Institute. The seven most severe defects -- critical congenital heart disease -- can affect the interior walls of the heart, important veins and arteries and the cardiac valves. This AWHONN SmartBrief special report looks at news and resources related to congenital heart defects. Part II will be published on April 22.
Advances in Care 
  • 35 states require life-saving heart screening for infants
    newborn feet  
    With the start of the year, 35 states require pulse oximetry screening for congenital heart defects, following the lead of Maryland and Indiana, which instituted mandatory testing in 2011. Expanding that to all states will help more infants live, said pediatric cardiologist Gerard Martin of Children's National Medical Center. "It's very important for us to find these babies early. If we find them, we can save 98 to 100 percent," Martin said. The Washington Post (tiered subscription model) (4/7)

CCHD Screening Saves Lives
Masimo SET® pulse oximeters and sensors meet the recommended criteria for newborn screening, were exclusively used in the two studies that were the basis for the CCHD Workgroup decision to recommend newborn screening, and were the first to receive FDA 510(k) clearance with labeling for CCHD screening. Learn more.
Trends and Technology 
  • Study shows promising results for pulmonary valve
    A study presented at an American College of Cardiology conference found that after a year Medtronic's Melody transcatheter pulmonary valve did not result in additional intervention, valve narrowing or substantial leakage in 94% of patients who received the device. The valve, which has humanitarian device exemption approval in the U.S., is delivered via a catheter to put off open-heart surgery in pediatric patients with congenital heart defects. Reuters (3/30)
  • Maternal biomarkers may predict cardiac defects
    Biomarkers in the mother's blood early in pregnancy may be associated with greater risk of congenital heart defects, according to research reported in the American Journal of Obstetrics & Gynecology. In the case-controlled study, the first-trimester serum from 27 mothers of children with congenital heart defects was compared with the serum of 59 mothers whose children did not have heart problems. The study team found that the risk could be modeled based on levels of the metabolites C3-OH, C5:1-DC and C14:2-OH. The next step could be to study the technique in larger trials. 2 Minute Medicine (4/9)
  • Mother's perspective: "Sienna seems like such a little fighter"
    The mother of a U.K. infant with tricuspid atresia and pulmonary atresia hopes her daughter does well enough to undergo surgery and perhaps come home after. The girl will likely need a heart transplant later in life if she survives. "Sienna seems like such a little fighter, she is so strong. And to look at her you wouldn't even know she was ill," Francesca Alfonso said. Liverpool Echo (U.K.) (4/8)
AWHONN Resources 
  • Webinar recording: CCHD Screening Using Pulse Oximetry
    Did you know that a 2-3 minute screening is all it takes to ensure that newborns in your hospital won't suffer complications or death from a missed diagnosis of CCHD? Congenital heart disease is the most common birth defect and accounts for almost 40% of deaths from congenital anomalies. Three out of every 1,000 babies are born with a severe form of CHD -- critical congenital heart disease (CCHD) -- and it is estimated that 2,000 will have a missed diagnosis or die. Nurses can help prevent complications from missing the diagnosis of CCHD by spending only a few minutes to screen newborns using pulse oximetry. Learn more and buy this webinar recording.

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual AWHONN endorsements. The news reported in SmartBrief does not necessarily reflect the official position of AWHONN.
Association of Women’s Health, Obstetric and Neonatal Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AWHONN is approved by the California Board of Registered Nursing, provider #CEP580.
Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director: Aaron Kern (202) 407-7866
Read more at SmartBrief.com
 Recent AWHONN SmartBrief Issues:   Editor: Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.® Legal Information